Personalized nanovaccines for treating solid cancer metastases
Abstract Cancer vaccines have garnered attention as a potential treatment for cancer metastases. Nevertheless, the clinical response rate to vaccines remains < 30%. Nanoparticles stabilize vaccines and improve antigen recognition and presentation, resulting in high tumor penetration or accumulati...
Saved in:
| Main Authors: | , , , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
BMC
2024-11-01
|
| Series: | Journal of Hematology & Oncology |
| Subjects: | |
| Online Access: | https://doi.org/10.1186/s13045-024-01628-4 |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
| _version_ | 1850064426514776064 |
|---|---|
| author | Tang Feng Jia Hu Jirui Wen Zhiyong Qian Guowei Che Qinghua Zhou Lingling Zhu |
| author_facet | Tang Feng Jia Hu Jirui Wen Zhiyong Qian Guowei Che Qinghua Zhou Lingling Zhu |
| author_sort | Tang Feng |
| collection | DOAJ |
| description | Abstract Cancer vaccines have garnered attention as a potential treatment for cancer metastases. Nevertheless, the clinical response rate to vaccines remains < 30%. Nanoparticles stabilize vaccines and improve antigen recognition and presentation, resulting in high tumor penetration or accumulation, effective co-distribution of drugs to the secondary lymphatic system, and adaptable antigen or adjuvant administration. Such vaccine-like nanomedicines have the ability to eradicate the primary tumors as well as to prevent or eliminate metastases. This review examines state-of-the-art nanocarriers developed to deliver tumor vaccines to metastases, including synthetic, semi-biogenic, and biogenic nanosystems. Moreover, it highlights the physical and pharmacological properties that enhance their anti-metastasis efficiency. This review also addresses the combination of nanovaccines with cancer immunotherapy to target various steps in the metastatic cascade, drawing insights from preclinical and clinical studies. The review concludes with a critical analysis of the challenges and frameworks linked to the clinical translation of cancer nanovaccines. |
| format | Article |
| id | doaj-art-1fdc425f697b4b5fbc013c3dccb12f9a |
| institution | DOAJ |
| issn | 1756-8722 |
| language | English |
| publishDate | 2024-11-01 |
| publisher | BMC |
| record_format | Article |
| series | Journal of Hematology & Oncology |
| spelling | doaj-art-1fdc425f697b4b5fbc013c3dccb12f9a2025-08-20T02:49:18ZengBMCJournal of Hematology & Oncology1756-87222024-11-0117115010.1186/s13045-024-01628-4Personalized nanovaccines for treating solid cancer metastasesTang Feng0Jia Hu1Jirui Wen2Zhiyong Qian3Guowei Che4Qinghua Zhou5Lingling Zhu6Department of Medical Oncology, Cancer Center, West China Hospital, Sichuan UniversityDepartment of Medical Oncology, Cancer Center, West China Hospital, Sichuan UniversityDeep Underground Space Medical Center, West China Hospital, Sichuan UniversityDepartment of Biotherapy, Cancer Center and State Key Laboratory of Biotherapy, West China Hospital, Sichuan UniversityLung Cancer Center/Lung Cancer Institute, West China Hospital, Sichuan UniversityLung Cancer Center/Lung Cancer Institute, West China Hospital, Sichuan UniversityDepartment of Medical Oncology, Cancer Center, West China Hospital, Sichuan UniversityAbstract Cancer vaccines have garnered attention as a potential treatment for cancer metastases. Nevertheless, the clinical response rate to vaccines remains < 30%. Nanoparticles stabilize vaccines and improve antigen recognition and presentation, resulting in high tumor penetration or accumulation, effective co-distribution of drugs to the secondary lymphatic system, and adaptable antigen or adjuvant administration. Such vaccine-like nanomedicines have the ability to eradicate the primary tumors as well as to prevent or eliminate metastases. This review examines state-of-the-art nanocarriers developed to deliver tumor vaccines to metastases, including synthetic, semi-biogenic, and biogenic nanosystems. Moreover, it highlights the physical and pharmacological properties that enhance their anti-metastasis efficiency. This review also addresses the combination of nanovaccines with cancer immunotherapy to target various steps in the metastatic cascade, drawing insights from preclinical and clinical studies. The review concludes with a critical analysis of the challenges and frameworks linked to the clinical translation of cancer nanovaccines.https://doi.org/10.1186/s13045-024-01628-4Cancer vaccineClinical translationMetastasisNanoparticleTumor |
| spellingShingle | Tang Feng Jia Hu Jirui Wen Zhiyong Qian Guowei Che Qinghua Zhou Lingling Zhu Personalized nanovaccines for treating solid cancer metastases Journal of Hematology & Oncology Cancer vaccine Clinical translation Metastasis Nanoparticle Tumor |
| title | Personalized nanovaccines for treating solid cancer metastases |
| title_full | Personalized nanovaccines for treating solid cancer metastases |
| title_fullStr | Personalized nanovaccines for treating solid cancer metastases |
| title_full_unstemmed | Personalized nanovaccines for treating solid cancer metastases |
| title_short | Personalized nanovaccines for treating solid cancer metastases |
| title_sort | personalized nanovaccines for treating solid cancer metastases |
| topic | Cancer vaccine Clinical translation Metastasis Nanoparticle Tumor |
| url | https://doi.org/10.1186/s13045-024-01628-4 |
| work_keys_str_mv | AT tangfeng personalizednanovaccinesfortreatingsolidcancermetastases AT jiahu personalizednanovaccinesfortreatingsolidcancermetastases AT jiruiwen personalizednanovaccinesfortreatingsolidcancermetastases AT zhiyongqian personalizednanovaccinesfortreatingsolidcancermetastases AT guoweiche personalizednanovaccinesfortreatingsolidcancermetastases AT qinghuazhou personalizednanovaccinesfortreatingsolidcancermetastases AT linglingzhu personalizednanovaccinesfortreatingsolidcancermetastases |